Physician profile
Aryles Hedjar
NPI 1861855454
$910.09
in general payments reported to CMS, 2019-2025
13 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $390 · 2024: $237 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.10 |
| Education | $130.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $209.99 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $168.99 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $148.50 | 2024-2025 | Tagrisso |
| Kite Pharma, INC. | $99.99 | 2022 | |
| Glaxosmithkline, LLC. | $88.30 | 2025 | Zejula, Jemperli, Ojjaara |
| Janssen Pharmaceuticals, INC | $41.02 | 2025 | |
| Accord Healthcare, INC. | $28.50 | 2025 | |
| Emd Serono, INC. | $24.20 | 2025 | |
| Pfizer INC. | $22.64 | 2025 | |
| Eisai INC. | $22.51 | 2024 | |
| Genzyme Corporation | $19.29 | 2025 | |
| Array Biopharma INC | $18.58 | 2025 | Mektovi, Braftovi, Tukysa |
| Abbvie INC. | $17.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aryles Hedjar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.